Market Executive Summary

REPORT HIGHLIGHT
The Nonalcoholic steatotic hepatitis (NASH)market is estimated to represent a global market of USD 2,298.6 million by 2028 with growth rate of 25.2%. Nonalcoholic steatotic hepatitis (NASH) is the most prevalent form of progressive liver disease condition. The market is categorized into serums biomarkers, Hepatic fibrosis biomarkers, Oxidative stress biomarkers, Apoptosis biomarkers, and others. Serum biomarkers segment held the largest share of the global market, accounted for more than 40% share. Benefits such as its ability to distinguish simple steatosis from NASH offers competitive advantage over other product segments. On contrary, hepatic fibrosis biomarkers is expected to grow with highest growth rate due to rising interest of companies to invest in this product.
However, poorly suited regulatory and reimbursement guidelines pose as a threat to the global market. As per the application section, pharmaceutical industry dominated the overall market. Increasing number of pharma companies involved in research activities of NASH drugs coupled with rising number of clinical studies augments the market growth. This market segment is also expected to grow with highest CAGR owing to the rising initiatives pertaining to the development of NASH drugs.

The spectrum of NAFLD & NASH is increasingly recognized both in the developed as well as developing region due to its prevalence in diabetes, insulin resistance syndrome and in obesity. North America has a well-established healthcare industry and the rising prevalence of NAFLD and NASH are expected to show a steady growth of the market during the coming years. According to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates,nearly 20% of people with NAFLD are affected by NASH.
Additionally, growing obese population coupled with increasing diabetic patients stimulate the uptake of NASH drugs hence drives the market growth. Current trends in developed regions indicated that the prevalence of obesity will cross more than 40% of the population by 2028. Meanwhile, number of patients affected with diabetes is also increasing at constant rate. These would in turn provides healthy platform for the growth of NASH drugs market during the future period.
Companies such as Allergan, Intercept, Prometheus Laboratories Inc., Gilead Sciences, Galmed Pharmaceuticals, Quest Diagnostic Incorporated, Enzo Biochem, Inc. Bio-Rad Laboratories, Inc. and others are considered to be the key players of this market.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Hospitals
Manufacturers
Traders, Distributors, And Suppliers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET,BY TYPES
Serums biomarkers
Hepatic fibrosis biomarkers
Oxidative stress biomarkers
Apoptosis biomarkers
Others
MARKET, BY APPLICATION
Pharma
Hospitals
Academic Institutes
others
MARKET,BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET,BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America